160 related articles for article (PubMed ID: 28833211)
21. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.
Titus RG; DeKrey GK; Morris RV; Soares MB
Infect Immun; 2001 Aug; 69(8):5189-92. PubMed ID: 11447205
[TBL] [Abstract][Full Text] [Related]
22. CXCL10 immunomodulatory effect against infection caused by an antimony refractory isolate of Leishmania braziliensis in mice.
Dutra BM; Rodrigues NLC; Fonseca FRM; de Moura TR; Pacheco de Almeida R; de Jesus AR; Abreu TM; Pompeu MML; Teixeira CR; Teixeira MJ
Parasite Immunol; 2021 Mar; 43(3):e12805. PubMed ID: 33131089
[TBL] [Abstract][Full Text] [Related]
23. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection.
Hoseini MH; Moradi M; Alimohammadian MH; Shahgoli VK; Darabi H; Rostami A
Parasitol Int; 2016 Apr; 65(2):99-104. PubMed ID: 26518128
[TBL] [Abstract][Full Text] [Related]
25. Oral treatment with zinc sulfate increases the expression of Th1 cytokines mRNA in BALB/c mice infected with Leishmania major.
Afshari M; Riazi-Rad F; Khaze V; Bahrami F; Ajdary S; Alimohammadian MH
Cytokine; 2016 May; 81():71-6. PubMed ID: 26896749
[TBL] [Abstract][Full Text] [Related]
26. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
27. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production.
Li J; Hunter CA; Farrell JP
J Immunol; 1999 Jan; 162(2):974-9. PubMed ID: 9916722
[TBL] [Abstract][Full Text] [Related]
28. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
29. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response.
Erb KJ; Blank C; Moll H
Immunol Cell Biol; 1996 Jun; 74(3):239-44. PubMed ID: 8799723
[TBL] [Abstract][Full Text] [Related]
31. Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.
Figueiredo WME; Viana SM; Alves DT; Guerra PV; Coêlho ZCB; Barbosa HS; Teixeira MJ
Mem Inst Oswaldo Cruz; 2017 Aug; 112(8):561-568. PubMed ID: 28767981
[TBL] [Abstract][Full Text] [Related]
32. Resolution of an infection with Leishmania braziliensis confers complete protection to a subsequent challenge with Leishmania major in BALB/c mice.
Lima HC; DeKrey GK; Titus RG
Mem Inst Oswaldo Cruz; 1999; 94(1):71-6. PubMed ID: 10029914
[TBL] [Abstract][Full Text] [Related]
33. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
34. Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with Leishmania major.
Mbow ML; Bleyenberg JA; Hall LR; Titus RG
J Immunol; 1998 Nov; 161(10):5571-7. PubMed ID: 9820534
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle.
Noormehr H; Zavaran Hosseini A; Soudi S; Beyzay F
Int Immunopharmacol; 2018 Jun; 59():97-105. PubMed ID: 29649772
[TBL] [Abstract][Full Text] [Related]
36. CD4+ Th1 cells induced by dendritic cell-based immunotherapy in mice chronically infected with Leishmania amazonensis do not promote healing.
Vanloubbeeck YF; Ramer AE; Jie F; Jones DE
Infect Immun; 2004 Aug; 72(8):4455-63. PubMed ID: 15271903
[TBL] [Abstract][Full Text] [Related]
37. The potential therapeutic effect of adipose-derived mesenchymal stem cells in the treatment of cutaneous leishmaniasis caused by L. major in BALB/c mice.
Bahrami S; Safari M; Razi Jalali MH; Ghorbanpoor M; Tabandeh MR; Rezaie A
Exp Parasitol; 2021 Mar; 222():108063. PubMed ID: 33412170
[TBL] [Abstract][Full Text] [Related]
38. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4.
Mocci S; Coffman RL
J Immunol; 1995 Apr; 154(8):3779-87. PubMed ID: 7706719
[TBL] [Abstract][Full Text] [Related]
39. EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.
Seif S; Kazemi F; Gholami E; Seyed N; Taslimi Y; Habibzadeh S; Azarian B; Jamshidi S; Hashemi M; Rafati S; Taheri T
Appl Microbiol Biotechnol; 2016 May; 100(9):3923-34. PubMed ID: 26685673
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
